Bridgebio Pharma, Inc. · NASDAQ:BBIO
Bridgebio Pharma — Merger or Acquisition (October 2020)
12 slides from Bridgebio Pharma's merger presentation, Oct 5, 2020
Slide 1: BridgeBio to acquire remaining minority interest in Eidos Therapeutics
BridgeBio to acquire remaining minority interest in Eidos Therapeutics October 5, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements and Disclaimer
Forward-Looking Statements and Disclaimer This Presentation contains statements relating to the proposed transaction involving BridgeBio Pharma, Inc. (the “Company”) and Eidos Therapeutics, Inc. (“Eidos”) that are not statements of historical fact. Such statements are considered forward-looking stat
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This Presentation is being made in respect of the proposed transaction involving the Company and Eidos, which will be submitted to the Company’s and Eidos’ stockholders for their consideration. The Company intends to file a registration statement on Form S
Slide 4: Transaction overview
Transaction overview BridgeBio Pharma (BridgeBio) to acquire all outstanding shares of Eidos Therapeutics (Eidos) not held by BridgeBio Subject to the terms and conditions of the agreement, Eidos stockholders will have the option to elect to receive either (i) 1.8500x shares of BridgeBio common stoc
Slide 5: BridgeBio fully and formally welcomes Eidos back into its ecosystem of innovation
BridgeBio fully and formally welcomes Eidos back into its vibrant ecosystem of innovation This agreement removes all barriers and allows us to fully unlock the potential of acoramidis for patients and investors Best owner hypothesis in orphan and RGD drugs = the passionate operators that connect sci
Slide 6: The time is now: commercial development is critical
The time is now: commercial development is critical given excitement around trial; new development opportunities need to be moved up in time ATTR-CM WT and hereditary Functional outcomes ATTR-CM WT and hereditary Functional outcomes + Composite mortality and morbidity ATTR-CM WT and hereditary Funct
Slide 7: Acoramidis will benefit from BridgeBio's growing suite of commercial capabilities
Acoramidis will benefit from BridgeBio’s growing suite of commercial capabilities… Centralized commercial functions BridgeBio commercial timelines Fosdenopterin for MoCD Type A NDA accepted Infigratinib for 2L+ CCA NDA filing expected 2H 2020 Acoramidis for ATTR-CM Phase 3 data late 2021 / early 202
Slide 8: …and a set of advisors and R&D leaders
…and a set of advisors and R&D leaders Selected R&D leaders Selected Clinical Advisors Charles Homcy, MD Chairman, Pharmaceuticals Richard Scheller, PhD Chairman, R&D Robert Harrington, MD Michael Gibson, MD Michael Kitt, MD Ethan Weiss, MD Dan Gretler, MD Senior leadership will guide ongoing and pl
Slide 9: Portfolio pipeline by segment and program
Portfolio segment Program Drug mechanism Diseases Patient pop. (US+EU) Modality Preclinical Clinical Discovery IND-enabling Phase1 Phase 2 Phase 3 Mendelian Acoramidis TTR stabilizer ATTR-CM >400K Fosdenopterin cPMP replacement MoCD type A 100 Infigratinib Low-dose FGFR1-3i Achondroplasia 55K Encale
Slide 10: BridgeBio drug engineering basics: our platform
Well described diseases than can be targeted at their source Tailored therapeutic technologies to create first or best-in-class medicines Broad clinical development capabilities across therapeutic areas and geographies Building the capabilities to deliver genetic medicines to patients globally Disco
Slide 11: The platform is delivering
Discover Novel genetic disease targets Create Medicines with industry-leading research capabilities Deliver Our products to patients through commercial infrastructure Test Our drugs through global development footprint 20+ Disclosed programs in the pipeline >10 INDs since 2015 15 Clinical trials acr
Slide 12: Four core value drivers over the next 12-18 months
Low-dose infigratinib (FGFRi) for achondroplasia Enrolling Ph2 study Dose first child Phase 2 data 2021 ATTR-CM Ph3 ongoing GLP tox ongoing File IND Phase 1/2 data 2021 Ph2 ongoing FPI in Ph2 study Phase 2 data 2021 Acoramidis: TTR stabilizer for ATTR Gene therapy for congenital adrenal hyperplasia
BridgeBio Pharma — Merger or Acquisition (October 2020) on 6ix